Recently, the Nanjing Jiangbei New District-based
Seiwa Genetics receives consecutive overseas orders
The family, which caters primarily to oncology patients
Biomedical companies conducting genetic testing
With excellent products
Not only the successful layout of the domestic
And it's already opened up overseas markets
"Currently, cancer treatment has entered the era of individualized precision medicine, and genetic testing, is a necessary prerequisite for the realization of precision medicine." Zhao Yvette Chao, co-founder and chief operating officer of Shihe Genetics, introduced thatThe work of Seiwa Genetics is to "map" the genes of cancer patients and assist doctors in developing individualized treatment plans for patients, taking into account clinical evidence.The
Screens for 9 types of cancer with just one tube of blood
Early screening of tumors is a common concern worldwide, and "early detection, early diagnosis, and early treatment" is currently the most effective strategy for fighting cancer.
The "Shiho Hawk-Eye" pan-cancer early screening product independently developed by Shiho Genetics.With just one tube of blood, you can screen for 9 types of cancers at once, including lung, liver, stomach, prostate, breast, esophageal, endometrial and pancreatic cancers.Once an abnormal signal is detected, the product can also locate the specific organ site from which the signal originated, thus greatly reducing the time required for tumor screening and diagnosis.
After the samples enter the medical testing laboratory at the headquarters of Seiwa Genetics, the entire testing process is recorded in an informationized manner by the proprietary Laboratory Information Management System (LIMS).Several processes are handled by automated equipment during the experimental session, and the whole process is highly specialized, automated and digitalized.
"After obtaining the CE certification of the European Union, 'Shihe Hawkeye' has been recognized as a breakthrough medical device by the U.S. FDA, becoming one of only four multi-cancer early screening products in the world to obtain this certification, and technically has reached the world's leading level."Zhao Yvette Chao introduced.
6.6 million yuan award for filling domestic gaps
previous year
S&G's self-developed
"Sehwa-1" kit is launched.
Once became the industry's "phenomenal" products
"Seiwa-1" kit
It is the first one in China to pass the National Drug Administration
Innovative medical devices approved and marketed
NGS Large Panel Oncology Genetic Testing Products
The product covers 425 key genes that are highly relevant to tumorigenesis, development and treatment prognosis through a single sample and a single test, thus calculating the tumor mutation load (TMB), providing more comprehensive molecular diagnostic and therapeutic information for tumor patients and helping doctors to make more accurate therapeutic decisions, which meets the growing clinical needs. Since the launch of the product, "Shiho-1" has been rapidly purchased by major hospitals nationwide.
"We have established cooperative relationships with hundreds of large tertiary and specialized tumor hospitals in China, including Jiangsu Provincial People's Hospital, Peking University Cancer Hospital, and the First Affiliated Hospital of Zhengzhou University." Zhao Yvetchao introduced.The breakthrough of "Shiho-1" is not only that it truly demonstrates the technological advantages of high-throughput sequencing, but also that its listing fills the gap in China, thus opening up a brand new situation for tumor NGS Large Panel products in hospital compliance testing.
In order to support the innovative development of the biomedical industry, Jiangsu Province, innovative pharmaceutical and equipment incentives to implement the program was formally introduced, the"Shiho No.1" was awarded 6.6 million RMB by the provincial government, and was also included in the provincial product catalog of new technologies and new products for popularization and application.
The second phase of the project was launched, significantly increasing production capacity
for the past many years
Seiwa Genetics has been focusing on scientific research and innovation
Continuous enhancement of research and development
Currently has nearly 60 domestic and foreign invention patents
A number of core technologies and products are the first of their kind in China
According to Zhao Yvetchao, talent is an important driving force for innovation. The company has set up wholly-owned R&D centers in Nanjing, China and Toronto, Canada, attracting and cultivating interdisciplinary and complex talents in the fields of tumor biology, molecular biology, bioinformatics and artificial intelligence.Relying on Nanjing's rich scientific and educational resources, Shiho Genetics has carried out industry-university-research cooperation with Nanjing Medical University, Southeast University, China Pharmaceutical University and many other universities, and continuously injected innovative vitality into the development of the enterprise through the construction of practice bases and the joint training of professional talents.
